Thermalsole und Schwefelbad Bentheim GmbH
- Address
- Am Bade 1, 48455 Bad Bentheim, Germany
Atopic Dermatitis and Eczema Research
At Thermalsole und Schwefelbad Bentheim GmbH, a major part of the clinical research portfolio focuses on immune system diseases and skin and connective tissue diseases, especially atopic dermatitis and related eczema conditions. These studies are designed to evaluate new treatment options, compare them with existing therapies, and better understand long-term control of itching and skin inflammation.
- Moderate-to-severe atopic dermatitis and chronic eczema
- Testing new therapies and comparing them with established treatments
- Long-term safety, symptom control, and improvement in skin symptoms
The site’s work in this area includes both adult and pediatric populations, reflecting a broad effort to improve care across age groups.
Psoriasis and Psoriatic Arthritis Studies
Another important research area covers psoriasis and psoriatic arthritis, with trials aimed at both skin symptoms and joint-related disease activity. These studies generally assess whether newer therapies can improve disease control, reduce flare-ups, and offer better outcomes for people living with persistent inflammatory disease.
- Plaque psoriasis, pustular psoriasis, and palmoplantar pustulosis
- Psoriatic arthritis and related inflammatory symptoms
- Evaluating treatment effectiveness and symptom improvement
This research area highlights the clinic’s strong focus on immune-mediated inflammatory conditions and practical treatment advances.
Alopecia Areata and Hair Loss Research
The clinical studies also include hormonal diseases and hair-related disorders, especially alopecia areata and other forms of hair loss. Research at the site is centered on finding treatments that can support hair regrowth, maintain response over time, and improve quality of life for patients affected by visible hair loss.
- Alopecia areata in children, adolescents, and adults
- Female androgenetic alopecia and other hair loss conditions
- Testing therapies intended to stimulate regrowth and sustain benefit
These studies reflect a growing interest in both the medical and psychosocial impact of chronic hair disorders.
Vitiligo and Skin Pigmentation Disorders
Research at the Klinisches Studienzentrum also includes vitiligo, particularly non-segmental forms that affect skin pigmentation. The studies are focused on evaluating whether emerging therapies can help restore pigment, improve visible skin changes, and provide durable disease control.
- Non-segmental vitiligo in adults and adolescents
- Improving repigmentation and disease stability
- Assessing treatment benefit in a chronic visible skin condition
This area adds to the site’s broader expertise in inflammatory and immune-related skin disease research.
Urticaria, Pruritus, and Itch-Driven Conditions
A further focus is on conditions marked by severe itching and recurrent skin symptoms, including chronic spontaneous urticaria, prurigo nodularis, and chronic pruritus-related disorders. These trials aim to improve itch relief, reduce skin lesions, and evaluate how well new treatments can control symptoms that strongly affect daily life.
- Chronic spontaneous urticaria and chronic pruritus
- Prurigo nodularis and lichen simplex chronicus
- Measuring symptom relief and overall treatment effectiveness
At Thermalsole und Schwefelbad Bentheim GmbH, this field supports research into better symptom management for patients with highly burdensome skin disease.
Cutaneous Lupus, Hidradenitis Suppurativa, and Other Immune-Mediated Skin Diseases
The site also participates in studies of less common but clinically significant immune system diseases, including cutaneous lupus erythematosus, hidradenitis suppurativa, and systemic sclerosis-associated interstitial lung disease. These trials are designed to assess whether new or existing therapies can improve disease activity, reduce inflammation, and provide longer-term safety information.
- Subacute and chronic cutaneous lupus erythematosus
- Hidradenitis suppurativa and related inflammatory skin disease
- Evaluating disease control, safety, and durability of response
The breadth of this research shows a strong commitment to complex immune-mediated conditions that often require specialized care.
Actinic Keratosis, Scabies, and Other Dermatology Trials
In addition to chronic inflammatory disorders, the research portfolio includes studies in other skin and connective tissue diseases such as actinic keratosis and scabies. These trials are aimed at evaluating whether treatments can clear affected skin areas more effectively and improve care for common dermatologic conditions.
- Actinic keratosis of the scalp and face
- Scabies and other treatable skin infestations
- Testing treatment effectiveness and skin clearance
This work broadens the site’s dermatology profile beyond inflammatory disease into preventive and therapeutic skin care research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 10 therapeutic areas and 15 of 66 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 65 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 23 by active trials.
- 1Novartis Pharma AG4active
lock +22 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG9trials
lock +20 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Thermalsole und Schwefelbad Bentheim GmbH
lock Showing 1 of 108 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 66 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Amlitelimab | 6 | Unknown | 2022-11-10 | 2024-10-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
